abrdn plc Invests $799,000 in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

abrdn plc purchased a new position in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 235,011 shares of the company's stock, valued at approximately $799,000. abrdn plc owned 0.59% of Vigil Neuroscience as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the stock. Point72 Asset Management L.P. acquired a new position in Vigil Neuroscience in the second quarter valued at approximately $5,940,000. Ensign Peak Advisors Inc raised its stake in shares of Vigil Neuroscience by 72.8% during the 2nd quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company's stock worth $1,580,000 after buying an additional 166,442 shares during the period. Vanguard Group Inc. raised its position in Vigil Neuroscience by 11.9% during the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company's stock worth $3,050,000 after acquiring an additional 95,276 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in Vigil Neuroscience during the second quarter valued at $87,000. Finally, Renaissance Technologies LLC grew its position in shares of Vigil Neuroscience by 19.2% in the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company's stock valued at $286,000 after purchasing an additional 11,536 shares during the period. Hedge funds and other institutional investors own 83.64% of the company's stock.

Vigil Neuroscience Stock Performance

Shares of NASDAQ:VIGL traded down $0.01 during trading on Tuesday, reaching $3.86. The company had a trading volume of 35,545 shares, compared to its average volume of 239,333. The firm has a market capitalization of $153.05 million, a PE ratio of -1.87 and a beta of 1.92. Vigil Neuroscience, Inc. has a twelve month low of $2.47 and a twelve month high of $7.07. The firm's fifty day moving average is $3.56 and its 200 day moving average is $3.62.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.02. Equities analysts predict that Vigil Neuroscience, Inc. will post -2.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on VIGL shares. Guggenheim decreased their target price on Vigil Neuroscience from $17.00 to $16.00 and set a "buy" rating for the company in a report on Wednesday, August 14th. HC Wainwright reiterated a "buy" rating and set a $17.00 target price on shares of Vigil Neuroscience in a research report on Wednesday, August 14th. Finally, Wedbush reaffirmed an "outperform" rating and set a $23.00 price objective on shares of Vigil Neuroscience in a report on Thursday, July 11th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to MarketBeat, Vigil Neuroscience currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.60.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.